6151-40-2
基本信息
奎寧定鹽酸鹽
奎尼丁單鹽酸鹽一水合物
奎尼丁 鹽酸鹽 一水合物
QUINIDINE HYDROCHLORIDE MONOHYDRATE
Quinidine monohydrate hydrochloride
Quinidine monohydrochloride monohydrate
QUINIDINE HYDROCHLORIDE ISO 9001:2015 REACH
QUINIDINE HYDROCHLORIDE MONOHYDRATE CRYSTALLINE
6μ-Methoxycinchonan-9-ol hydrochloride monohydrate
Quinidine hydrochloride monohydrate technical grade
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
2024/11/08 | HY-B1302 | 奎寧定鹽酸鹽 Quinidine hydrochloride monohydrate | 6151-40-2 | 100mg | 500元 |
2024/11/08 | HY-B1302 | 奎寧定鹽酸鹽 Quinidine hydrochloride monohydrate | 6151-40-2 | 10mM * 1mLin DMSO | 550元 |
常見問題列表
IC50: 19.9 μM (K + channel)
Quinidine hydrochloride monohydrate blocks WT mSlo3 (K Ca 5.1) channels with an IC 50 of 19.9±1.41?μM and Hill slope of 1.15±0.15 (n=7). Again, the potency of inhibition by Quinidine hydrochloride monohydrate is higher for F304Y mSlo3 (IC 50 of 2.42±0.60?μM, n=9, P<0.005; Hill slope of 0.98±0.12), but lower with R196Q mSlo3 (IC 50 of 38.4±6.77?μM, n=5, P<0.001; Hill slope of 1.05±0.16). The inhibition of F304Y mSlo3 by Quinidine hydrochloride monohydrate is observed to have some time dependence.
Direct application of Quinidine hydrochloride monohydrate on the sciatic nerve produces a dose-related decrease in amplitude at ascending somato-sensory evoked potential (SSEP) and descending compound muscle action potentials (CMAP) when comparing baseline with other time points, or when comparing the experimental left limb to the right contra-lateral glucose-treated limb. The latencies of SSEPs and CMAP potentials after Quinidine hydrochloride monohydrate applications are increased compare to baseline and the contralateral side.